Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Novatek will build the gas pipeline to Murmansk

10/11/23 NVTK

Investment in Rosneft and Pertamina refineries in Indonesia expected in 2024

10/11/23 ROSN

Polymetal repurchased 2.5 thousand common shares under the exchange offer

10/11/23 POLY

More than 20% of Green Crab's fleet is idle due to Evolute's childhood illnesses

10/11/23 HYDR

Etalon Group sales for 9 months of 2023 increased by 62%

10/11/23 ETLN

Samokat may start producing food products

10/11/23 SBER

Segezha Group launched a new woodworking center

10/11/23 SGZH

Rusal has allocated sales volumes for 2023

10/11/23 RUAL

Magnit intends to buy back up to 7.9% more of its shares

10/11/23 MGNT

Gazprom to build Russia's largest gas turbine blade production facility

10/10/23 GAZP